Brief: Sellas Life Sciences Provides Update On Phase 3 Regal Clinical Trial For Galinpepimut-S In Acute Myeloid Leukemia

Sellas Life Sciences

12/10/2023 21:13

Oct 12 (Reuters) - Sellas Life Sciences Group Inc
 SLS.O :
    * SELLAS LIFE SCIENCES PROVIDES UPDATE ON PHASE 3 REGAL
CLINICAL
TRIAL FOR GALINPEPIMUT-S IN ACUTE MYELOID LEUKEMIA
    * SELLAS LIFE SCIENCES GROUP INC - ENROLLMENT IN CHINA
EXPECTED TO
COMMENCE THIS QUARTER
    * SELLAS LIFE SCIENCES GROUP INC - ENROLLMENT EX-CHINA
EXPECTED TO
BE COMPLETED IN NOVEMBER 2023
    * SELLAS LIFE SCIENCES GROUP INC - NEXT MEETING OF
INDEPENDENT
DATA MONITORING COMMITTEE FOR REGAL STUDY IS SCHEDULED FOR END
OF NOVEMBER 2023
    * SELLAS LIFE SCIENCES GROUP INC - INTERIM ANALYSIS (AFTER
60
EVENTS) IS ON TRACK TO OCCUR IN LATE 2023 OR EARLY 2024 FOR
REGAL STUDY

Source text for Eikon:  ID:nGNXbWVk8h 
Further company coverage:  SLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))